Copaxone and Memantine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Copaxone and Memantine. Common interactions include fall among females and balance disorder among males.

The phase IV clinical study analyzes what interactions people who take Copaxone and Memantine have. It is created by eHealthMe based on reports of 17 people who take Copaxone and Memantine from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 30, 2022

17 people who take Copaxone and Memantine together, and have interactions are studied.


What is Copaxone?

Copaxone has active ingredients of glatiramer acetate. It is often used in multiple sclerosis. eHealthMe is studying from 54,209 Copaxone users for its effectiveness, alternative drugs and more.

What is Memantine?

Memantine has active ingredients of memantine. It is often used in alzheimer's disease. eHealthMe is studying from 7,747 Memantine users for its effectiveness, alternative drugs and more.

Number of Copaxone and Memantine reports submitted per year:

Copaxone and Memantine drug interactions.

Common Copaxone and Memantine drug interactions by gender *:

female:

  1. Fall
  2. Malaise
  3. Vision blurred
  4. Balance disorder
  5. Fatigue
  6. Anxiety
  7. Chest pain
  8. Daydreaming
  9. Flushing
  10. Heart rate increased

male:

  1. Balance disorder
  2. Fall
  3. Anaphylactic reaction
  4. Angioedema
  5. Crying
  6. Peripheral swelling

Common Copaxone and Memantine drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Anxiety
  2. Chest pain
  3. Daydreaming
  4. Flushing
  5. Heart rate increased
  6. Injection site erythema
  7. Injection site mass
  8. Injection site pain
  9. Injection site pruritus
  10. Injection site reaction

40-49:

  1. Depression
  2. Gait disturbance
  3. Memory impairment
  4. Vision blurred

50-59:

  1. Arthropathy
  2. Cardiac failure congestive
  3. Chronic obstructive pulmonary disease
  4. Injection site necrosis
  5. Mental status changes
  6. Muscle atrophy
  7. Pneumonia

60+:

  1. Fall
  2. Balance disorder
  3. Peripheral swelling
  4. Bedridden
  5. Malaise
  6. Fatigue
  7. Gait disturbance
  8. Somnolence
  9. Anaphylactic reaction
  10. Angioedema

Common conditions people have *:

  1. Pain: 2 people, 11.76%
  2. Mental Disorder (a psychological term for a mental or behavioural pattern or anomaly that causes distress or disability): 2 people, 11.76%
  3. Dizziness: 2 people, 11.76%
  4. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 1 person, 5.88%
  5. High Blood Pressure: 1 person, 5.88%
  6. Depression: 1 person, 5.88%
  7. Complex Regional Pain Syndrome (long lasting pain condition most often affecting one of the limbs (arms, legs, hands, or feet)): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Copaxone and Memantine?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Copaxone and Memantine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Copaxone interactions:

Browse all interactions between Copaxone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Memantine interactions:

Browse all interactions between Memantine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on glatiramer acetate and memantine (the active ingredients of Copaxone and Memantine, respectively), and Copaxone and Memantine (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Copaxone and Memantine.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: